
Albireo Pharma, Inc. (NASDAQ: ALBO), relating to its proposed sale to Ipsen. Under the terms of the agreement, ALBO shareholders are expected to receive $42.00 in cash per share they own, plus one Contingent Value Right worth a deferred $10.00 per share.